Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05730205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary and study completion dates: Jun 15, 2026 to Mar 2027Start date: Jun 8, 2023 to Aug 2, 2023 · Trial status: Recruiting to Active, Not Recruiting · Eligibility criteria expanded, about 16 words · 1 morev8Show 4 more changesShow less
Start date: Jun 8, 2023 to Aug 2, 2023
Trial status: Recruiting to Active, Not Recruiting
NotablePrimary and study completion dates: Jun 15, 2025 to Jun 15, 2026v7
MinorPrimary and study completion dates: Feb 15, 2025 to Jun 15, 2025v6
NotablePrimary and study completion dates: Feb 15, 2024 to Feb 15, 2025v5
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1 · Start date changed from estimate of May 15, 2023 to Jun 8, 2023v4Show 2 more changesShow less
Study sites: 0 to 1
Start date changed from estimate of May 15, 2023 to Jun 8, 2023
Show 2 earlier versionsHide 2 earlier versions
NotableStart date: Mar 30, 2023 to May 15, 2023v3
NotableStart date: Feb 15, 2023 to Mar 30, 2023v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.